Medical Stocks

PerkinElmer Inc Valuation – July 2016 $PKI

Benjamin Graham taught that Intelligent Investors must do a thorough fundamental analysis of investment opportunities to determine their intrinsic value and inherent risk.  This is best done by utilizing a systematic approach to analysis that will provide investors with a sense of how a specific company compares to another company or by reviewing the 10 Companies Benjamin Graham Would Invest In Today – June 2016.  By using the ModernGraham method one can review a company’s historical accomplishments and determine an intrinsic value that can be compared across industries.  What follows is a stock analysis showing a specific look at how PerkinElmer Inc (PKI) fares in the ModernGraham valuation model.

Company Profile (obtained from Google Finance): PerkinElmer, Inc. is a provider of products, services and solutions to the diagnostics, research, environmental and laboratory markets. The Company’s operating segments include Human Health, Environmental Health and Corporate. The Human Health segment concentrates on developing diagnostics, tools and applications to help detect diseases earlier. Within its Human Health segment, the Company serves the diagnostics and research markets. It provides early detection for genetic disorders from pregnancy to early childhood, as well as flat panel X-ray detectors and infectious disease testing for the diagnostics market. The Environmental Health segment provides products, services and solutions to facilitate the creation of safer food and consumer products, secure surroundings and energy resources. The Environmental Health segment serves the environmental, industrial and laboratory services markets. The Company markets its products and services in over 150 countries.

[level-free]

To read the details of this valuation, you must be logged in as a premium member. If you are not a premium member, please consider becoming one.

Premium members can view a full ModernGraham valuation of the company and have access to download a PDF version of the valuation for easy reference. Here is a free sample valuation pdf, and here is a post detailing what can be found within each individual company’s valuation.

[/level-free]
[not-level-free]

Downloadable PDF version of this valuation:

ModernGraham Valuation of PKI – July 2016

Stage 1: Is this company suitable for the Defensive Investor or the Enterprising Investor?

What kind of Intelligent Investor are you?

Defensive Investor; must pass 6 out of the following 7 tests.
1. Adequate Size of the Enterprise Market Cap > $2Bil $5,830,524,978 Pass
2. Sufficiently Strong Financial Condition Current Ratio > 2 1.89 Fail
3. Earnings Stability Positive EPS for 10 years prior Pass
4. Dividend Record Dividend Payments for 10 years prior Pass
5. Earnings Growth Increase of 33% in EPS in past 10 years using 3 year averages at beginning and end 107.96% Pass
6. Moderate PEmg Ratio PEmg < 20 27.28 Fail
7. Moderate Price to Assets PB Ratio < 2.5 OR PB*PEmg < 50 2.86 Fail
Enterprising Investor; must pass 4 out of the following 5 tests, or be suitable for the Defensive Investor.
1. Sufficiently Strong Financial Condition Current Ratio > 1.5 1.89 Pass
2. Sufficiently Strong Financial Condition Debt to NCA < 1.1 2.26 Fail
3. Earnings Stability Positive EPS for 5 years prior Pass
4. Dividend Record Currently Pays Dividend Pass
5. Earnings Growth EPSmg greater than 5 years ago Pass

Stage 2: Determination of Intrinsic Value

PKI value chart July 2016

EPSmg $1.93
MG Growth Estimate 12.82%
MG Value $65.89
Opinion Fairly Valued
MG Grade C
MG Value based on 3% Growth $27.99
MG Value based on 0% Growth $16.41
Market Implied Growth Rate 9.39%
Current Price $52.66
% of Intrinsic Value 79.93%

PerkinElmer, Inc. is suitable for the Enterprising Investor but not the more conservative Defensive Investor. The Defensive Investor is concerned with the low current ratio, high PEmg and PB ratios. The Enterprising Investor is only concerned with the level of debt relative to the net current assets. As a result, all Enterprising Investors following the ModernGraham approach should feel comfortable proceeding with the analysis.

As for a valuation, the company appears to be Fairly Valued after growing its EPSmg (normalized earnings) from $1.04 in 2012 to an estimated $1.93 for 2016. This level of demonstrated earnings growth supports the market’s implied estimate of 9.39% annual earnings growth over the next 7-10 years. As a result, the ModernGraham valuation model, based on Benjamin Graham’s formula, returns an estimate of intrinsic value within a margin of safety relative to the price.

PerkinElmer, Inc. receives an average overall rating in the ModernGraham grading system, scoring a C.

Stage 3: Information for Further Research

PKI charts July 2016

Net Current Asset Value (NCAV) -$10.00
Graham Number $33.99
PEmg 27.28
Current Ratio 1.89
PB Ratio 2.86
Current Dividend $0.28
Dividend Yield 0.53%
Number of Consecutive Years of Dividend Growth 0

[/not-level-free]

Useful Links:

ModernGraham tagged articles Morningstar
Google Finance MSN Money
Yahoo Finance Seeking Alpha
GuruFocus SEC Filings

Most Recent Balance Sheet Figures

Balance Sheet Information 3/1/2016
Total Current Assets $1,049,820,000
Total Current Liabilities $554,547,000
Long-Term Debt $1,119,830,000
Total Assets $4,210,721,000
Intangible Assets $2,777,744,000
Total Liabilities $2,161,241,000
Shares Outstanding (Diluted Average) 111,195,000

Earnings Per Share History

Next Fiscal Year Estimate $2.75
Dec2015 $1.87
Dec2014 $1.39
Dec2013 $1.47
Dec2012 $0.61
Dec2011 $0.07
Dec2010 $3.25
Dec2009 $0.73
Dec2008 $1.07
Dec2007 $1.09
Dec2006 $0.95
Dec2005 $2.04
Dec2004 $0.74
Dec2003 $0.41
Dec2002 -$1.21
Dec2001 $0.33
Dec2000 $0.89
Dec1999 $1.66
Dec1998 $1.11
Dec1997 $0.37
Dec1996 $0.64

Earnings Per Share – ModernGraham History

Next Fiscal Year Estimate $1.93
Dec2015 $1.37
Dec2014 $1.20
Dec2013 $1.15
Dec2012 $1.04
Dec2011 $1.25
Dec2010 $1.70
Dec2009 $1.01
Dec2008 $1.16
Dec2007 $1.15
Dec2006 $0.98
Dec2005 $0.82
Dec2004 $0.22
Dec2003 $0.11
Dec2002 $0.16
Dec2001 $0.85
Dec2000 $1.05

Recommended Reading:

Other ModernGraham posts about the company

PerkinElmer Inc Valuation – January 2016 Update $PKI
PerkinElmer Inc. Analysis – October 2015 Update $PKI
PerkinElmer Inc. Analysis – October 2015 Update $PKI
5 Speculative and Overvalued Companies to Avoid – October 2014
14 Companies in the Spotlight This Week – 10/18/14

Other ModernGraham posts about related companies

Varian Medical Systems Inc Valuation – July 2016 $VAR
St. Jude Medical Inc Valuation – June 2016 $STJ
Zimmer Biomet Holdings Inc Valuation – June 2016 $ZBH
Waters Corporation Valuation – May 2016 $WAT
Align Technology Inc Valuation – May 2016 $ALGN
C.R. Bard Inc Stock Valuation – February 2016 $BCR
Psychemedics Corp Stock Valuation – February 2016 $PMD
Patterson Companies Inc Stock Valuation – February 2016 $PDCO
Edwards Lifesciences Corp Valuation – February 2016 $EW
Baxter International Inc Valuation – February 2016 $BAX

Disclaimer:

The author did not hold a position in any company mentioned in this article at the time of publication and had no intention of changing that position within the next 72 hours.  See my current holdings here.  This article is not investment advice; any reader should speak to a registered investment adviser prior to making any investment decisions.  ModernGraham is not affiliated with the company in any manner.  Please be sure to review our detailed disclaimer.

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Back To Top